Human Appeal’s first U.S. domestic campaign aims to collect 3,500 coats for families in need ...

Evaluation of liver biopsies from SYMMETRY using AI-assisted digital pathology (HistoIndex) corroborated the fibrosis improvements previously demonstrated by conventional pathology and revealed that ...

HCW Biologics debuted the results from its preclinical study of HCW11-018b, the Company’s lead T-cell engager product candidate, that highlights the uniqueness and advantages of its second-generation ...

The FDA in October requested additional sensitivity analyses of clinical efficacy data from Rhythm’s Phase 3 pivotal trial in acquired hypothalamic obesity. No new data were requested. The additional ...

Raised 2025 total net revenue guidance to $854.0 million to $873.0 million, adjusted non-GAAP EBITDA to $221.0 million to $228.0 million, and adjusted non-GAAP diluted earnings per share of $7.37 to ...

Dr. John Kellum, Chief Medical Officer of Spectral Medical, stated, “The positive Tigris results confirm a clinically meaningful survival benefit with PMX, validating our Bayesian approach and years ...

Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, ...

Studies spanning cardiovascular, aging, and cancer biology highlight how Seer’s Proteograph® platform is enabling discovery at population scale ...

For the three months ended September 30, 2025, operating income totaled $1.5 million, compared to $2.0 million in Q3 2024 and $1.9 million in Q2 2025. Q3 2025 operating expenses included $1.4 million ...

Fleurieux-sur-l’Arbresle – France – 7 novembre 2025 – Dans le cadre de sa sortie de procédure de redressement judiciaire, Safe (FR0014002U25 – ALSAF) s'est rendue, ce jour, au Palais de Justice de ...

CLEVELAND, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Wednesday, November 12, 2025 at 8:30 a.m. ET to discuss its third ...

CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic ...